Microsize antibodies for $99 | Learn More >>

Monoclonal Antibody Western Blotting CYR61

Also showing Monoclonal Antibody Western Blotting Intussusceptive Angiogenesis, Monoclonal Antibody Intussusceptive Angiogenesis

$122
20 µl
$293
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Flow Cytometry, Immunofluorescence (Immunocytochemistry), Western Blotting

Background: Cysteine-rich protein 61 (CYR61, CCN1) is a secreted, matrix-associated protein belonging to the CCN family, a protein group characterized primarily by its high cysteine content (1). CYR61 regulates diverse cellular events including cell proliferation, differentiation, angiogenesis, and extracellular matrix formation. Research studies have implicated CYR61 in the development or progression of various cancers, including breast, prostate, lung, and hepatocellular carcinoma (1-4). Notably, its role in promoting cancer progression appears to be context-dependent. For example, investigators have shown that overexpression of CYR61 was positively associated with invasiveness of breast cancer cell lines (2), whereas in primary prostate tumors, expression levels were inversely correlated with tumor aggressiveness (3). In additional research studies of hepatocellular carcinoma, where CYR61 expression was positively associated with cancer progression, CYR61 was shown to be transcriptionally regulated by the Wnt/β-catenin signaling pathway (1).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse

Application Methods: Western Blotting

Background: Cysteine-rich protein 61 (CYR61, CCN1) is a secreted, matrix-associated protein belonging to the CCN family, a protein group characterized primarily by its high cysteine content (1). CYR61 regulates diverse cellular events including cell proliferation, differentiation, angiogenesis, and extracellular matrix formation. Research studies have implicated CYR61 in the development or progression of various cancers, including breast, prostate, lung, and hepatocellular carcinoma (1-4). Notably, its role in promoting cancer progression appears to be context-dependent. For example, investigators have shown that overexpression of CYR61 was positively associated with invasiveness of breast cancer cell lines (2), whereas in primary prostate tumors, expression levels were inversely correlated with tumor aggressiveness (3). In additional research studies of hepatocellular carcinoma, where CYR61 expression was positively associated with cancer progression, CYR61 was shown to be transcriptionally regulated by the Wnt/β-catenin signaling pathway (1).